{"id":4730,"date":"2025-06-19T23:03:27","date_gmt":"2025-06-19T23:03:27","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/06\/19\/readout-loud-podcast-fda-sarepta-verdun-gene-therapy-harvard\/"},"modified":"2025-06-19T23:03:27","modified_gmt":"2025-06-19T23:03:27","slug":"readout-loud-podcast-fda-sarepta-verdun-gene-therapy-harvard","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/06\/19\/readout-loud-podcast-fda-sarepta-verdun-gene-therapy-harvard\/","title":{"rendered":"FDA\u2019s gene therapy turmoil, and an alternative model for funding research"},"content":{"rendered":"<p>    FDA\u2019s gene therapy turmoil, and an alternative model for funding research<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p>Why did the Food and Drug Administration suddenly oust one of its top gene therapy regulators? Is the agency growing too political? And should private firms fund academic research?<\/p>\n<p>We chat about all that and more on this on this week\u2019s episode of \u201cThe Readout LOUD,\u201d STAT\u2019s biotech podcast. We discuss the <a href=\"https:\/\/www.statnews.com\/2025\/06\/15\/duchenne-sarepta-gene-therapy-elevidys-patient-death\/\">tragic news<\/a> that a second teenage boy with Duchenne muscular dystrophy died after taking Sarepta Therapeutics\u2019 gene therapy, <a href=\"https:\/\/www.statnews.com\/2025\/06\/16\/duchenne-muscular-dystrophy-community-reacts-second-death-sarepta-therapeutics-elevidys\/\">raising renewed questions<\/a> about the FDA\u2019s  standards for approving drugs.<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/06\/19\/readout-loud-podcast-fda-sarepta-verdun-gene-therapy-harvard\/?utm_campaign=rss\">Read the rest\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Elaine Chen, Adam Feuerstein, and Allison DeAngelis<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/06\/19\/readout-loud-podcast-fda-sarepta-verdun-gene-therapy-harvard\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA\u2019s gene therapy turmoil, and an alternative model for funding research Why did the Food and Drug Administration suddenly oust one of its top gene therapy regulators? Is the agency growing too political? And should private firms fund academic research? We chat about all that and more on this on this week\u2019s episode of \u201cThe [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2154,2146,2659,2155,2151,2265],"tags":[2150],"class_list":["post-4730","post","type-post","status-publish","format-standard","hentry","category-biotechnology","category-fda","category-gene-therapy","category-pharmaceuticals","category-policy","category-the-readout-loud","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/4730"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=4730"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/4730\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=4730"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=4730"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=4730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}